The incidence of cardiac adverse events ( all grades ) was 16.4 % in the placebo arm and 14.5 % in the pertuzumab arm , with left ventricular systolic dysfunction ( LVSD , all grades ) being the most frequently reported event ( 8.3 % versus 4.4 % in the placebo and pertuzumab arm ) .
